Natco Pharma
- All
- News
- Videos
-
Stocks To Watch: PowerGrid Corporation, Novartis India, Natco Pharma
PowerGrid Corporation reported a 6 per cent rise in consolidated net profit to Rs 3,526.23 crore in the quarter ended March 2021 from Rs 3,313.47 crore in the same quarter last fiscal
-
Natco Pharma Gains On Getting Emergency Use Approval Of COVID-19 Drug
Natco Pharma shares gained as much as 4.27% to hit an intraday high of Rs 935 after it received emergency use approval for drug to treat COVID-19 patients.
-
Amid Caution, These Stocks Lose Upto 8% In Run Up To RBI Policy
Natco Pharma, Vakrangee, Redington, NTPC and HCL Technologies posted heavy losses on Wednesday.
-
Natco Pharma Surges 20%, Partner's Drug Gets USFDA Nod
Natco Pharma shares surged on the news. Its shares were locked at upper circuit of Rs 954.35, a jump of 20 per cent.
-
Natco To Launch Generic Vidaza In US Market Soon
Vidaza generated total combined sales of $188 million for the twelve-month period ending April 2017, based on industry sales data.
-
Cancer Drug Prices Slashed Up To 86% In A Year: Regulator
The other pharma players the prices whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.
-
Natco Pharma Did Not Follow Quality Control Measures: USFDA
The FDA had inspected the Kothur formulation facility between January 16-24, 2017, Natco Pharma said in a statement.
-
USFDA Makes 6 Observations At Natco Pharma's Kothur Facility
Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to the address the USFDA observations.
-
Natco May Launch Leukemia Drug In US Maket On Or Before Nov 2019
Natco and Breckenridge filed their ANDA with a Paragraph IV certification on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers,
-
Natco Pharma Launches Generic Influenza Treatment Capsules In US
In August this year, Natco Pharma received a final approval for its abbreviated new drug application for generic versions of Tamiflu oral capsules from the US drug regulator.
-
Natco To File Over 10 New Drug Applications In US In Next Two Fiscals
Drug firm Natco Pharma is aiming to file over 10 Abbreviated New Drug Applications (ANDAs) in the US in the next two financial years to expand its presence in the American market.
-
Natco Pharma Gets Inspection Report From USFDA For Chennai Facility
Drug firm Natco Pharma has received the Establishment Inspection Report for its chemical division facility in Chennai from the US health regulator after closure of inspection.
-
US Patent Office Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma on Thursday said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
Natco Pharma Q1 Net Jumps 70% To Rs 47.65 Crore
Natco Pharma on Tuesday reported 69.75 per cent increase in consolidated net profit to Rs 47.65 crore for the first quarter ended June 30, 2016.
-
Stocks To Watch: PowerGrid Corporation, Novartis India, Natco Pharma
PowerGrid Corporation reported a 6 per cent rise in consolidated net profit to Rs 3,526.23 crore in the quarter ended March 2021 from Rs 3,313.47 crore in the same quarter last fiscal
-
Natco Pharma Gains On Getting Emergency Use Approval Of COVID-19 Drug
Natco Pharma shares gained as much as 4.27% to hit an intraday high of Rs 935 after it received emergency use approval for drug to treat COVID-19 patients.
-
Amid Caution, These Stocks Lose Upto 8% In Run Up To RBI Policy
Natco Pharma, Vakrangee, Redington, NTPC and HCL Technologies posted heavy losses on Wednesday.
-
Natco Pharma Surges 20%, Partner's Drug Gets USFDA Nod
Natco Pharma shares surged on the news. Its shares were locked at upper circuit of Rs 954.35, a jump of 20 per cent.
-
Natco To Launch Generic Vidaza In US Market Soon
Vidaza generated total combined sales of $188 million for the twelve-month period ending April 2017, based on industry sales data.
-
Cancer Drug Prices Slashed Up To 86% In A Year: Regulator
The other pharma players the prices whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.
-
Natco Pharma Did Not Follow Quality Control Measures: USFDA
The FDA had inspected the Kothur formulation facility between January 16-24, 2017, Natco Pharma said in a statement.
-
USFDA Makes 6 Observations At Natco Pharma's Kothur Facility
Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to the address the USFDA observations.
-
Natco May Launch Leukemia Drug In US Maket On Or Before Nov 2019
Natco and Breckenridge filed their ANDA with a Paragraph IV certification on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers,
-
Natco Pharma Launches Generic Influenza Treatment Capsules In US
In August this year, Natco Pharma received a final approval for its abbreviated new drug application for generic versions of Tamiflu oral capsules from the US drug regulator.
-
Natco To File Over 10 New Drug Applications In US In Next Two Fiscals
Drug firm Natco Pharma is aiming to file over 10 Abbreviated New Drug Applications (ANDAs) in the US in the next two financial years to expand its presence in the American market.
-
Natco Pharma Gets Inspection Report From USFDA For Chennai Facility
Drug firm Natco Pharma has received the Establishment Inspection Report for its chemical division facility in Chennai from the US health regulator after closure of inspection.
-
US Patent Office Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma on Thursday said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
US Rules In Mylan's Favour, Invalidates Teva Patents: Natco
Drug firm Natco Pharma said the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals' patents related to multiple sclerosis drug Copaxone 40 mg/mL.
-
Natco Pharma Q1 Net Jumps 70% To Rs 47.65 Crore
Natco Pharma on Tuesday reported 69.75 per cent increase in consolidated net profit to Rs 47.65 crore for the first quarter ended June 30, 2016.
